Literature DB >> 8985426

Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.

S I Takao1, K Kiyotani, T Sakaguchi, Y Fujii, M Seno, T Yoshida.   

Abstract

Mechanisms of protection of mice from Sendai virus, which is exclusively pneumotropic and causes a typical respiratory disease, by immunization with recombinant vaccinia viruses (RVVs) were investigated. Although the RVV carrying a hemagglutinin-neuraminidase gene of Sendai virus (Vac-HN) propagated in the noses and lungs of mice by either intranasal (i.n.) or intraperitoneal (i.p.) inoculation, no vaccinia virus antigens were detected in the mucosal layer of upper and lower airways of the i.p.-inoculated mice. The mice immunized i.n. with Vac-HN or Vac-F (the RVV carrying a fusion protein gene of Sendai virus) demonstrated the strong resistance to Sendai virus challenge both in the lung and in the nose, whereas the i.p.-immunized mice showed almost no resistance in the nose but showed a partial resistance in the lung. Titration of Sendai virus-specific antibodies in the nasal wash (NW), bronchoalveolar lavage (BAL), and serum collected from the Vac-F-immunized mice showed that the NW from the i.n.-immunized mice contained immunoglobulin A (IgA) antibodies but no IgG and the BAL from the mice contained both IgA and IgG antibodies. On the other hand, neither IgA nor IgG antibodies were detected in the NW from the i.p.-immunized mice and only IgG antibodies were detected in the BAL, although both i.n.- and i.p.-immunized mice exhibited similar levels of serum IgG, IgA, and neutralizing antibodies. The resistance to Sendai virus in the noses of i.n.-immunized mice could be abrogated by the intranasal instillation of anti-mouse IgA but not of anti-IgG antiserum, while the resistance in the lung was not significantly abrogated by such treatments. These results demonstrate that IgA is a major mediator for the immunity against Sendai virus induced by the RVVs and IgG is a supplementary one, especially in the lung, and that the RVV should be intranasally inoculated to induce an efficient mucosal immunity even if it has a pantropic nature.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985426      PMCID: PMC191127     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine.

Authors:  C A Meitin; B S Bender; P A Small
Journal:  Vaccine       Date:  1991-10       Impact factor: 3.641

2.  Protective effect of serum antibody on respiratory infection of influenza C virus in rats.

Authors:  K Takiguchi; K Sugawara; S Hongo; H Nishimura; F Kitame; K Nakamura
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Comparison of protective effects of serum antibody on respiratory and systemic infection of Sendai virus in mice.

Authors:  M Tashiro; K Tobita; J T Seto; R Rott
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

4.  Passive transfer of local immunity to influenza virus infection by IgA antibody.

Authors:  K B Renegar; P A Small
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

5.  Immunoglobulin A mediation of murine nasal anti-influenza virus immunity.

Authors:  K B Renegar; P A Small
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Local and systemic immunity to influenza infections in ferrets.

Authors:  W H Barber; P A Small
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

8.  Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.

Authors:  G A Prince; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans.

Authors:  T A Brown; B R Murphy; J Radl; J J Haaijman; J Mestecky
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

10.  Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis.

Authors:  R Ramphal; R C Cogliano; J W Shands; P A Small
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

View more
  6 in total

1.  Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis.

Authors:  A Kato; K Kiyotani; Y Sakai; T Yoshida; T Shioda; Y Nagai
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

3.  Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses.

Authors:  Margareta Flock; Karin Jacobsson; Lars Frykberg; Timothy R Hirst; Anders Franklin; Bengt Guss; Jan-Ingmar Flock
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

4.  Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses.

Authors:  Yan Zhang; Jingyi Yang; Rong Bao; Yaoqing Chen; Dihan Zhou; Benxia He; Maohua Zhong; Yaoming Li; Fang Liu; Qiaoli Li; Yi Yang; Chen Han; Ying Sun; Yuan Cao; Huimin Yan
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

Review 5.  Recombinant vaccines against the mononegaviruses--what we have learned from animal disease controls.

Authors:  Hiroki Sato; Misako Yoneda; Tomoyuki Honda; Chieko Kai
Journal:  Virus Res       Date:  2011-10-05       Impact factor: 3.303

6.  PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.

Authors:  Wei-wei Gai; Yan Zhang; Di-han Zhou; Yao-qing Chen; Jing-yi Yang; Hui-min Yan
Journal:  Virol Sin       Date:  2011-04-07       Impact factor: 4.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.